Researchers at Johns Hopkins University School of Medicine have found that a common antibiotic used to treat urinary tract infections may have a role in breast cancer treatment. The researchers have found that the drug, nitroxoline, could slow or even stop the spread of breast cancer cells, according to Fox News
Nitroxoline's clinical trials are still underway, but the early returns have been a success. The antibiotic blocks the formation of new blood vessels which can lead to tumor development.
"Angiogenesis, the growth of new blood vessels, plays an important role in tumor growth and metastasis, so inhibiting angiogenesis is a promising strategy for developing new anticancer drugs," Dr. Jun O. Liu, professor of pharmacology and molecular sciences at Johns Hopkins, told the news source.
The researchers used mice to test the antibiotic and the results were convincing. Nitroxoline reduced breast cancer cell tumor volume by 60 percent, which could give patients a better chance of survival.
According to BreastCancer.org, there are over 2.5 million breast cancer survivors living in the United States.